Medical Marijuana Inc Announces Positive Developments in Recent Studies Using Cannabidiol (CBD) Compound; NBC News, ABC News and Huffington Post Report California Pacific Medical Center’s Findings That CBD Stops Metastasis in Aggressive Cancers – The Wall Street Journal

“Medical Marijuana Inc Announces Positive Developments in Recent Studies Using Cannabidiol (CBD) Compound; NBC News, ABC News and Huffington Post Report California Pacific Medical Center’s Findings That CBD Stops Metastasis in Aggressive Cancers

SAN DIEGO, May 28, 2013 (GLOBE NEWSWIRE) — Medical Marijuana Inc (OTC Pink:MJNA) is pleased to inform shareholders and the general public of recent developments in the research involving Cannabidiol (CBD) and other Phyto-cannabinoids.

The Following is taken from a Huffington Post interview with Dr. McAllister and Dr. Desprez:

A pair of scientists at California Pacific Medical Center in San Francisco has found that a compound derived from marijuana could stop metastasis in many kinds of aggressive cancer, potentially altering the fatality of the disease forever.

“It took us about 20 years of research to figure this out, but we are very excited,” said Pierre Desprez, one of the scientists behind the discovery, to The Huffington Post. “We want to get started with trials as soon as possible.”

The Daily Beast first reported on the finding, which has already undergone both laboratory and animal testing, and is awaiting permission for clinical trials in humans.

Desprez, a molecular biologist, spent decades studying ID-1, the gene that causes cancer to spread. Meanwhile, fellow researcher Sean McAllister was studying the effects of Cannabidiol, or CBD, a non-toxic, non-psychoactive chemical compound found in the cannabis plant. Finally, the pair collaborated, combining CBD and cells containing high levels of ID-1 in a petri dish.

“What we found was that his Cannabidiol could essentially ‘turn off’ the ID-1,” Desprez told HuffPost. The cells stopped spreading and returned to normal.

“We likely would not have found this on our own,” he added. “That’s why collaboration is so essential to scientific discovery.”

Desprez and McAllister first published a paper about the finding in 2007. Since then, their team has found that CBD works both in the lab and in animals. And now, they’ve found even more good news.

“We started by researching breast cancer,” said Desprez. “But now we’ve found that Cannabidiol works with many kinds of aggressive cancers–brain, prostate–any kind in which these high levels of ID-1 are present.”

Desprez hopes that clinical trials will begin immediately.

“We’ve found no toxicity in the animals we’ve tested, and Cannabidiol is already used in humans for a variety of other ailments,” he said. Indeed, the compound is used to relieve anxiety and nausea, and, since it is non-psychoactive, does not cause the “high” associated with THC.

While marijuana advocates will surely praise the discovery, Desprez explained that it’s not so easy as just lighting up.

“We used injections in the animal testing and are also testing pills,” he said. “But you could never get enough Cannabidiol for it to be effective just from smoking.”

Additional Information:

Dr. McAllister & CBD Research

Dr. Sean McAllister says that he is ready to begin testing CBD on humans to evaluate anti-cancer properties. Dr. McAllister and colleague Pierre Desprez, PhD from California Pacific Medical Center have previously mentioned, “Cannabidiol offers hope of a non-toxic therapy that could treat aggressive forms of cancer without any of the painful side effects of chemotherapy.” “We found that this one compound, CBD, had a specific effect on metastatic cancer cells, very aggressive tumor cells. CBD in animal studies has been used to ‘switch off’ a specific gene regulator.” Dr. McAllister explains: “We find when you treat with CBD, you down regulate the expression of this protein and that inhibits the disease process.” Dr. McAllister and Dr. Desprez have developed a synthetic version of CBD, which they say targets a specific gene in the body related to the spread of cancer (metastasis). Article: http://abclocal.go.com/kgo/story?section=news/health&id=9057615

Additional Cannabidiol Information

ABC News-

http://abclocal.go.com/kgo/story?section=news/health&id=9057615

Huffington Post-

http://www.huffingtonpost.com/2012/09/19/marijuana-and-cancer_n_1898208. html?ncid=edlinkusaolp00000003&ir=Weird%20News

US. National Cancer Institute

http://www.cancer.gov/cancertopics/pdq/cam/cannabis/healthprofessional/p age4

Additional Dr. McAllister Publications

http://www.ncbi.nlm.nih.gov/pubmed/?term=Sean%20McAllister

Additional Published Material on Cannabidiol (CBD)

http://www.ncbi.nlm.nih.gov/gquery/?term=CANNABIDIOL”

More: http://online.wsj.com/article/PR-CO-20130528-906109.html

Marijuana mouth spray for cancer patients tough to abuse – NBC

Image result for nbc news vitals

“The medical marijuana drug Sativex, which could be approved in the United States in the coming years as a treatment for pain relief, has little potential for abuse, experts say.

The British pharmaceutical company GW Pharmaceuticals is currently testing the drug, which is delivered as a mouth spray and called Sativex, in clinical trials. The company plans to seek U.S. Food and Drug Administration approval for the drug as a treatment for cancer pain when the trials are completed, likely sometime in 2014, a spokesperson for GW Pharmaceuticals told MyHealthNewsDaily.

The active ingredients in Sativex, known as cannabinoids, are derived from the cannabis plant. It is the first marijuana-based drug to be made by extracting the compounds from the plant, rather than synthesizing them. Two other drugs, Marinol and Cesamet, based on synthetic cannabinoids, were approved by the FDA in the 1980s.”

More: http://vitals.nbcnews.com/_news/2012/01/31/10280678-marijuana-mouth-spray-for-cancer-patients-tough-to-abuse?lite

Bay Area Researchers Claim Cannabis Can Cure Cancer

“Marijuana has been used for medicinal purposes–relieving stress and pain and fighting hunger and nausea–for centuries if not millennia. But now, a pair of doctors in San Francisco claim that they’ve compiled reliable data showing that a certain compound in cannabis–cannabidiol–may actually cure cancer.”

Bay Area Researchers Claim Cannabis Can Cure Cancer

“Unlike THC, the ingredient in marijuana that makes you feel stoned, cannabidiol is a non-toxic compound of the plant that has no psychoactive qualities, and it’s been the focus of an ongoing series of trials at the San Francisco-based California Pacific Medical Center. There, physicians Sean McAllister and Pierre Desprez claim they’ve successfully used cannabidiol to fight animal genes involved in the spread of cancer. Now they hope to be allowed to conduct anti-cancer research using cannabidiol on actual humans.”

Cannabinoid receptor systems: therapeutic targets for tumour intervention.

Image result for taylor & francis online

“The past decade has witnessed a rapid expansion of our understanding of the biological roles of cannabinoids and their cognate receptors. It is now certain that Delta9-tetrahydrocannabinol, the principle psychoactive component of the Cannabis sativa plant, binds and activates membrane receptors of the 7-transmembrane domain, G-protein-coupled superfamily.

Several putative endocannabinoids have since been identified, including anandamide, 2-arachidonyl glycerol and noladin ether. Synthesis of numerous cannabinomimetics has also greatly expanded the repertoire of cannabinoid receptor ligands with the pharmacodynamic properties of agonists, antagonists and inverse agonists.

Collectively, these ligands have proven to be powerful tools both for the molecular characterisation of cannabinoid receptors and the delineation of their intrinsic signalling pathways. Much of our understanding of the signalling mechanisms activated by cannabinoids is derived from studies of receptors expressed by tumour cells; hence, this review provides a succinct summary of the molecular pharmacology of cannabinoid receptors and their roles in tumour cell biology.

Moreover, there is now a genuine expectation that the manipulation of cannabinoid receptor systems may have therapeutic potential for a diverse range of human diseases. Thus, this review also summarises the demonstrated antitumour actions of cannabinoids and indicates possible avenues for the future development of cannabinoids as antitumour agents.” http://www.ncbi.nlm.nih.gov/pubmed/14640910

http://www.tandfonline.com/doi/abs/10.1517/14728222.7.6.749

The endocannabinoid system and its therapeutic exploitation.

Image result for Nat Rev Drug Discov.

“The term ‘endocannabinoid’ – originally coined in the mid-1990s after the discovery of membrane receptors for the psychoactive principle in Cannabis, Delta9-tetrahydrocannabinol and their endogenous ligands – now indicates a whole signalling system that comprises cannabinoid receptors, endogenous ligands and enzymes for ligand biosynthesis and inactivation. This system seems to be involved in an ever-increasing number of pathological conditions. With novel products already being aimed at the pharmaceutical market little more than a decade since the discovery of cannabinoid receptors, the endocannabinoid system seems to hold even more promise for the future development of therapeutic drugs. We explore the conditions under which the potential of targeting the endocannabinoid system might be realized in the years to come.”  http://www.ncbi.nlm.nih.gov/pubmed/15340387

http://www.nature.com/nrd/journal/v3/n9/full/nrd1495.html

Active Component Of Marijuana Has Anti-Cancer Effects, Study Suggests

“Guillermo Velasco and colleagues, at Complutense University, Spain, have provided evidence that suggests that cannabinoids such as the main active component of marijuana (THC) have anticancer effects on human brain cancer cells.

In the study, THC was found to induce the death of various human brain cancer cell lines and primary cultured human brain cancer cells by a process known as autophagy.

Consistent with the in vitro data, administration of THC to mice with human tumors decreased tumor growth and induced the tumor cells to undergo autophagy. As analysis of tumors from two patients with recurrent glioblastoma multiforme (a highly aggressive brain tumor) receiving intracranial THC administration showed signs of autophagy, the authors suggest that cannabinoid administration may provide a new approach to targeting human cancers.”  http://www.sciencedaily.com/releases/2009/04/090401181217.htm

“Cannabinoid action induces autophagy-mediated cell death through stimulation of ER stress in human glioma cells” https://www.jci.org/articles/view/37948

 

Federal Government Reports Marijuana Effective in Combatting Certain Cancers Reports ADSI – NBC News

“LOS ANGELES, March 12, 2013 (GLOBE NEWSWIRE) — The following is a statement by Advocates for the Disabled and Seriously Ill:

In a recent report, the National Cancer Institute (NCI), part of the Federal government’s National Institutes of Health (NIH), stated that marijuana “inhibited the survival of both estrogen receptor–positive and estrogen receptor–negative breast cancer cell lines.” The same report showed marijuana slows or stops the growth of certain lung cancer cells and suggested that marijuana may provide “risk reduction and treatment of colorectal cancer.”

Referring to the NCI report, Patient Rights attorney Matthew Pappas said, “The Federal government’s continuing attack on people prescribed medical cannabis by their doctors is hypocritical considering the benefits reported by its own National Cancer Institute.” Pappas represents patients in defending their right to reasonably obtain medical marijuana. The patients contend the Federal government and various municipalities are trying to prevent them from obtaining cannabis for medical purposes in direct contravention of state laws. “Cities that ban dispensaries are denying patients the ability to obtain a medicine the Federal government’s National Institutes of Health says fights cancer and they’re doing it with the Obama Administration’s help.” Recently, the City of Los Angeles repealed its ban of medical marijuana collectives after Bill Rosendahl, a member of its city council diagnosed with cancer and prescribed medical marijuana said to fellow council members about the ban, “You want to kill me? You want to throw me under the bus?”

The NCI report also examined whether patients who smoke marijuana rather than ingesting it orally are exposed to a higher risk of lung and certain digestive system cancers. According to the government, 19 studies “failed to demonstrate statistically significant associations between marijuana inhalation and lung cancer.” The report also identified a separate study of 611 lung cancer patients that showed marijuana was “not associated with an increased risk of lung cancer or other upper aerodigestive tract cancers and found no positive associations with any cancer type.” In the area of prostate cancer, the NCI report was inconclusive and suggested further research was necessary. In its report, the National Cancer Institute also identified a “study of intratumoral injection of delta-9-THC in patients with recurrent glioblastoma” that showed tumor reduction in the test participants.

Despite the Federal government sanctioned and authorized NCI report, Pappas said Congress and the Obama Administration have continued to thwart marijuana research. In an announced effort to displace state medical marijuana laws, the Office of National Drug Control Policy described “medical” marijuana as a “myth” fueling “troubling misconceptions” in documents found on its website. The Federal government appears to be focused on creating more chemical drugs, many of which are the subject of various attorney television commercials seeking out those adversely impacted by those drugs. Pappas said both the Drug Enforcement Administration and the Office of National Drug Control Policy continue to assert marijuana lacks any medicinal value despite the research showing cannabis reduces certain cancer risks and inhibits the growth of tumor cells. He also commented that the Federal government’s anti-marijuana position contributes to and encourages prejudice and public misconception about the legitimate use of medical cannabis as treatment for seriously ill patients.

In addition to anti-cancer properties, separate research reported marijuana appears to have “profound nerve-protective and brain-enhancing properties that could potentially treat many neurodegenerative disorders.” In its report, the National Cancer Institute stated cannabis effectively treats insomnia and referenced a placebo-controlled study in cancer patients showing increased quality of sleep and relaxation in those treated with tetrahydrocannabinol, an active component in marijuana.

Responding to a White House statement that only a small percentage of patients prescribed medical cannabis under state laws use it to treat cancer, Pappas said “marijuana isn’t just for cancer or AIDS patients – it can also treat, for example, sleeplessness.” Although generally not a life threatening condition, Pappas referred to insomnia as a health issue regularly treated with prescription drugs zolpidem (brand name Ambien) and eszopiclone (brand name Lunesta). According to their manufacturers’ websites, zolpidem and eszopiclone have been shown to cause severe side effects including aggressiveness, hallucinations, confusion, or suicidal thoughts. Pappas noted that, unlike those drugs, studies on insomnia similar to those reported by the National Cancer Institute show medical marijuana effectively treats insomnia at a far lower cost and with fewer side effects. Marijuana has also been prescribed for glaucoma, multiple sclerosis, chronic pain, and a variety of other physical and mental conditions.

Addressing the White House website statement that medical marijuana should remain criminally illegal under federal law, Pappas said that “with every drug, the doctor must consider the benefits versus any possible side effects. In its 3000-plus year history of medicinal use, there has never been a known, confirmed death caused by overdose of marijuana. To suggest that prescription drugs known to have severe negative side effects are alright and that marijuana can only be used for cancer or AIDS is nonsensical. It demonstrates how the Federal government’s decision to usurp state sovereignty is harming people because burdening citizens with federal criminal records based on medical marijuana provided for under state law is simply wrong. To continue outlawing the use of a drug shown to have life-saving, anti-cancer benefits that has been used safely as a medication for thousands of years is irresponsible.”

Jan., 2013 National Cancer Institute PDQ® report on cannabis:

www.cancer.gov/cancertopics/pdq/cam/cannabis/healthprofessional/page2

July, 2009 NIH report on cannabis reducing neck and head squamous cell carcinoma:

www.ncbi.nlm.nih.gov/pubmed/19638490

Nov., 2012 NIH report on cannabis breast cancer treatment:

www.ncbi.nlm.nih.gov/pubmed/22776349

Report on study showing smoked marijuana does not cause cancer:

www.washingtonpost.com/wp-dyn/content/article/2006/05/25/AR2006052501729.html

Report on neuroprotective benefits of marijuana:

www.foxnews.com/health/2012/03/20/researchers-study-neuroprotective-properties-in-cannabis/

White House “Fact Sheet” on Marijuana Legalization:

http://www.whitehouse.gov/sites/default/files/ondcp/Fact_Sheets/marijuana_legalization_fact_sheet_3-3-11.pdf

Office of National Drug Control Policy documents:

www.whitehouse.gov/sites/default/files/page/files/marijuana_fact_sheet_3-28-12.pdf and

www.whitehouse.gov/sites/default/files/ondcp/issues-content/medical_marijuana_information_packet.pdf

For more information, contact Advocates for the Disabled and Seriously Ill at (213) 531-1788.”

http://www.nbcnews.com/id/51148243/ns/business-press_releases/t/federal-government-reports-marijuana-effective-combatting-certain-cancers-reports-adsi/

Cannabinoids may be therapeutic in breast cancer.

“Cannabinoids are a group of compounds synthesized exclusively by the Cannabis sativa plant, commonly known as marijuana. In 1990, the first cannabinoid-specific membrane (CB1) was characterized and cloned (Matsuda, Lolait, Brownstein, Young, & Bonner, 1990), which catapulted biomedical research on these unique compounds.

 Cannabinoids refer to both marijuana-derived compounds with the active ingredient of 9-tetrahydrocannabinol (THC) and also the synthetic molecules that activate the same primary targets as THC.

Therapeutic properties of marijuana have been well established; however, the clinical use of either plant-sourced or pure cannabinoids remains limited.

The anticachexia properties of cannabinoids are found in tetrahydrocannabinol (oral capsules of synthetically generated THC) and are used to manage weight loss, wasting syndrome, and nausea and vomiting associated with cancer treatment.”

http://www.ncbi.nlm.nih.gov/pubmed/23448745

Pot Fights Breast Cancer

“For years, cancer patients have used pot to combat the side effects of chemotherapy. But evidence has grown, both clinical and anecdotal, that cannabis has the potential to impede the spread of cancer itself. 

Now, researchers in Japan are reporting that CBDA keeps breast cancer cells from spreading. 

CBD, the miracle of component of cannabis that has been shown to have profound efficacy as a pain reliever, is obtained from its parent molecule, cannabidiolic acid or CBDA.

Until now, investigators have wondered whether CBDA is biologically active. But the study reports: “CBDA is an inhibitor of highly aggressive human breast cancer cell migration.””-

by Dan Skye

http://hightimes.com/news/dskye/7912

More: http://www.sciencedirect.com/science/article/pii/S0378427412012854

Role of cannabinoid and vanilloid receptors in invasion of human breast carcinoma cells.

“It is known that the diversified effects of cannabinoid on the fate of carcinoma cells are mediated predominantly through receptors. However, little is known about the effects of the individual activities of cannabinoid and noncannabinoid receptors. Here we investigate the role of cannabinoid receptor (CB) 1, CB2, and transient receptor potential vanilloid type 1 in cell proliferation and invasion patterns in the MDA-MB-231 cell line.

Our results showed that activation of CB1 and vanilloid receptors by methanandamide, a nonselective agonist, and arachidonyl-2′-choloroethylamide (ACEA) and N-oleoyldopamine, selective agonists, reduced invasion of MDA-MB-231 cells at pharmacological concentrations. Accordingly, CB1 activation resulted in decreased expression of matrix metalloproteinase (MMP) 2. On the other hand, administration of a CB2 agonist (CB65) increased cell invasion and expression of MMP2. The data obtained from MTT assay did not show any correlation between reduced invasion and cytotoxic effects of drugs. In addition, the level of vascular endothelial growth factor was significantly reduced in treatment with (R)-(+)-methanandamide, ACEA, CB65, and AM251 (a potent agonist for GPR55 and selective antagonist of CB1) compared with control. Elevated expression of cyclooxygenase-2 was observed in all of the MDA-MB-231 cells treated with agonists.

These results underline the influence of cannabinoid and vanilloid receptors on the invasiveness of MDA-MB-231 human breast carcinoma cells.”

http://www.ncbi.nlm.nih.gov/pubmed/23394450